The global high affinity nerve growth factor receptor market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of cancer and chronic pain, and increasing number of clinical trials for the treatment of these diseases.
The global high affinity nerve growth factor receptor market is segmented on the basis of type, application, and region. On the basis of type, it is segmented into AS7962, AZ7451, BN27, Cenegermin CR0089. On the basis of application it is segmented into bile duct cancer (BCC), papillary thyroid cancer (PTC), low back pain (LBP), lung cancer (LC). On the basis of region it includes North America (NA), Latin America (LA), Europe(EU) Asia Pacific & Middle East & Africa(APMEA).
Some Of The Growth Factors Of This Market:
- Increasing prevalence of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease is driving the growth of the global High Affinity Nerve Growth Factor Receptor market.
- Increasing geriatric population base in developing countries such as China and India is also driving the growth of the global High Affinity Nerve Growth Factor Receptor market.
- Rising awareness about neurodegenerative diseases among people in developed countries such as US, Japan, Germany, France, UK and Italy is also driving the growth of the global High Affinity Nerve Growth Factor Receptor market.
- Growing research activities on neurodegenerative diseases are expected to fuel demand for high affinity nerve growth factor receptor drugs.
Industry Growth Insights published a new data on “High Affinity Nerve Growth Factor Receptor Market”. The research report is titled “High Affinity Nerve Growth Factor Receptor Market research by Types (ASP-7962, AZD-7451, BNN-27, Cenegermin, CRB-0089, Others), By Applications (Bile Duct Cancer, Papillary Thyroid Cancer, Low Back Pain, Lung Cancer, Others), By Players/Companies Array BioPharma Inc, Astellas Pharma Inc, AstraZeneca Plc, Daiichi Sankyo Co Ltd, Dompe Farmaceutici SpA, Genzyme Corp, Handok Inc, Ignyta Inc, Loxo Oncology Inc, Merck & Co Inc, Nerviano Medical Sciences Srl, Plexxikon Inc, Proximagen Ltd, Rottapharm Biotech Srl, Sienna Biopharmaceuticals Inc, Tiziana Life Sciences Plc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
High Affinity Nerve Growth Factor Receptor Market Research Report
By Type
ASP-7962, AZD-7451, BNN-27, Cenegermin, CRB-0089, Others
By Application
Bile Duct Cancer, Papillary Thyroid Cancer, Low Back Pain, Lung Cancer, Others
By Companies
Array BioPharma Inc, Astellas Pharma Inc, AstraZeneca Plc, Daiichi Sankyo Co Ltd, Dompe Farmaceutici SpA, Genzyme Corp, Handok Inc, Ignyta Inc, Loxo Oncology Inc, Merck & Co Inc, Nerviano Medical Sciences Srl, Plexxikon Inc, Proximagen Ltd, Rottapharm Biotech Srl, Sienna Biopharmaceuticals Inc, Tiziana Life Sciences Plc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global High Affinity Nerve Growth Factor Receptor Market Report Segments:
The global High Affinity Nerve Growth Factor Receptor market is segmented on the basis of:
Types
ASP-7962, AZD-7451, BNN-27, Cenegermin, CRB-0089, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Bile Duct Cancer, Papillary Thyroid Cancer, Low Back Pain, Lung Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Array BioPharma Inc
- Astellas Pharma Inc
- AstraZeneca Plc
- Daiichi Sankyo Co Ltd
- Dompe Farmaceutici SpA
- Genzyme Corp
- Handok Inc
- Ignyta Inc
- Loxo Oncology Inc
- Merck & Co Inc
- Nerviano Medical Sciences Srl
- Plexxikon Inc
- Proximagen Ltd
- Rottapharm Biotech Srl
- Sienna Biopharmaceuticals Inc
- Tiziana Life Sciences Plc
Highlights of The High Affinity Nerve Growth Factor Receptor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ASP-7962
- AZD-7451
- BNN-27
- Cenegermin
- CRB-0089
- Others
- By Application:
- Bile Duct Cancer
- Papillary Thyroid Cancer
- Low Back Pain
- Lung Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the High Affinity Nerve Growth Factor Receptor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
High affinity nerve growth factor receptor (HAGFR) is a protein that binds to nerve growth factor (NGF). HAGFR is found on the surface of cells in the central nervous system. NGF stimulates the growth and survival of neurons.
Some of the major players in the high affinity nerve growth factor receptor market are Array BioPharma Inc, Astellas Pharma Inc, AstraZeneca Plc, Daiichi Sankyo Co Ltd, Dompe Farmaceutici SpA, Genzyme Corp, Handok Inc, Ignyta Inc, Loxo Oncology Inc, Merck & Co Inc, Nerviano Medical Sciences Srl, Plexxikon Inc, Proximagen Ltd, Rottapharm Biotech Srl, Sienna Biopharmaceuticals Inc, Tiziana Life Sciences Plc.
The high affinity nerve growth factor receptor market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. High Affinity Nerve Growth Factor Receptor Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. High Affinity Nerve Growth Factor Receptor Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. High Affinity Nerve Growth Factor Receptor Market - Supply Chain
4.5. Global High Affinity Nerve Growth Factor Receptor Market Forecast
4.5.1. High Affinity Nerve Growth Factor Receptor Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. High Affinity Nerve Growth Factor Receptor Market Size (000 Units) and Y-o-Y Growth
4.5.3. High Affinity Nerve Growth Factor Receptor Market Absolute $ Opportunity
5. Global High Affinity Nerve Growth Factor Receptor Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Type
5.3.1. ASP-7962
5.3.2. AZD-7451
5.3.3. BNN-27
5.3.4. Cenegermin
5.3.5. CRB-0089
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global High Affinity Nerve Growth Factor Receptor Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Application
6.3.1. Bile Duct Cancer
6.3.2. Papillary Thyroid Cancer
6.3.3. Low Back Pain
6.3.4. Lung Cancer
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global High Affinity Nerve Growth Factor Receptor Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global High Affinity Nerve Growth Factor Receptor Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global High Affinity Nerve Growth Factor Receptor Demand Share Forecast, 2019-2029
9. North America High Affinity Nerve Growth Factor Receptor Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Application
9.4.1. Bile Duct Cancer
9.4.2. Papillary Thyroid Cancer
9.4.3. Low Back Pain
9.4.4. Lung Cancer
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Type
9.7.1. ASP-7962
9.7.2. AZD-7451
9.7.3. BNN-27
9.7.4. Cenegermin
9.7.5. CRB-0089
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America High Affinity Nerve Growth Factor Receptor Demand Share Forecast, 2019-2029
10. Latin America High Affinity Nerve Growth Factor Receptor Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Application
10.4.1. Bile Duct Cancer
10.4.2. Papillary Thyroid Cancer
10.4.3. Low Back Pain
10.4.4. Lung Cancer
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Type
10.7.1. ASP-7962
10.7.2. AZD-7451
10.7.3. BNN-27
10.7.4. Cenegermin
10.7.5. CRB-0089
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America High Affinity Nerve Growth Factor Receptor Demand Share Forecast, 2019-2029
11. Europe High Affinity Nerve Growth Factor Receptor Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Application
11.4.1. Bile Duct Cancer
11.4.2. Papillary Thyroid Cancer
11.4.3. Low Back Pain
11.4.4. Lung Cancer
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe High Affinity Nerve Growth Factor Receptor Market Size and Volum Forecast by Type
11.7.1. ASP-7962
11.7.2. AZD-7451
11.7.3. BNN-27
11.7.4. Cenegermin
11.7.5. CRB-0089
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe High Affinity Nerve Growth Factor Receptor Demand Share, 2019-2029
12. Asia Pacific High Affinity Nerve Growth Factor Receptor Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Application
12.4.1. Bile Duct Cancer
12.4.2. Papillary Thyroid Cancer
12.4.3. Low Back Pain
12.4.4. Lung Cancer
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Type
12.7.1. ASP-7962
12.7.2. AZD-7451
12.7.3. BNN-27
12.7.4. Cenegermin
12.7.5. CRB-0089
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific High Affinity Nerve Growth Factor Receptor Demand Share, 2019-2029
13. Middle East & Africa High Affinity Nerve Growth Factor Receptor Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Application
13.4.1. Bile Duct Cancer
13.4.2. Papillary Thyroid Cancer
13.4.3. Low Back Pain
13.4.4. Lung Cancer
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa High Affinity Nerve Growth Factor Receptor Market Size and Volume Forecast by Type
13.7.1. ASP-7962
13.7.2. AZD-7451
13.7.3. BNN-27
13.7.4. Cenegermin
13.7.5. CRB-0089
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa High Affinity Nerve Growth Factor Receptor Demand Share, 2019-2029
14. Competition Landscape
14.1. Global High Affinity Nerve Growth Factor Receptor Market: Market Share Analysis
14.2. High Affinity Nerve Growth Factor Receptor Distributors and Customers
14.3. High Affinity Nerve Growth Factor Receptor Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Array BioPharma Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Astellas Pharma Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AstraZeneca Plc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Daiichi Sankyo Co Ltd
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Dompe Farmaceutici SpA
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Genzyme Corp
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Handok Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Ignyta Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Loxo Oncology Inc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Merck & Co Inc
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Nerviano Medical Sciences Srl
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Plexxikon Inc
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Proximagen Ltd
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Rottapharm Biotech Srl
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Sienna Biopharmaceuticals Inc
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Tiziana Life Sciences Plc
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
